GlassScriptPhysician profile
Jessica Trevino
NPI 1912946484
$10,105.29
in general payments reported to CMS, 2019-2025
38 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $353 · 2021: $457 · 2022: $1,476 · 2023: $2,139 · 2024: $2,530 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,960 · Education: $57.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,960.32 |
| Education | $57.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,556.91 | 2019-2025 | Exalt Model D, X-Tack Endoscopic Helix Tacking System, Wallflex Duodenal |
| Abbvie INC. | $1,425.21 | 2021-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $874.92 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $750.74 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $565.47 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $540.32 | 2022-2025 | |
| Genzyme Corporation | $357.95 | 2022-2025 | |
| Celgene Corporation | $308.71 | 2022-2024 | Zeposia |
| Covidien LP | $235.52 | 2019-2020 | |
| Ambu INC. | $235.33 | 2020-2021 | |
| Lilly USA, LLC | $170.55 | 2024-2025 | Omvoh |
| Medtronic, INC. | $163.06 | 2022 | |
| Olympus America INC. | $161.40 | 2023 | Endoclot Phs, Single Use Aspiration Needle Na-U200h, Visiglide |
| Conmed Corporation | $160.75 | 2023 | Conmed Generators, Conmed Biliary |
| Regeneron Healthcare Solutions, INC. | $148.18 | 2022-2025 | Dupixent |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $133.67 | 2023-2025 | |
| Cook Medical LLC | $113.86 | 2019 | |
| Madrigal Pharmaceuticals | $111.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Medrobotics INC. | $108.27 | 2019 | |
| Ardelyx, INC. | $104.84 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $101.55 | 2023-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $100.03 | 2022-2023 | |
| Ethicon US, LLC | $94.28 | 2019 | |
| Ironwood Pharmaceuticals, INC | $84.97 | 2022-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $78.08 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $59.93 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $57.40 | 2024 | Zymfentra |
| Daiichi Sankyo INC. | $55.78 | 2022-2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $35.75 | 2023-2024 | Givlaari |
| Pharmacosmos Therapeutics INC. | $31.30 | 2023 | Monoferric |
| Amgen INC. | $27.46 | 2023 | Amjevita, Avsola |
| Enterra Medical, INC. | $24.54 | 2024 | |
| Fresenius Kabi USA, LLC | $24.48 | 2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $24.02 | 2025 | Ultomiris |
| Novo Nordisk INC | $22.86 | 2025 | Wegovy |
| Organon LLC | $19.23 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.99 | 2023 | Ocaliva |
| Vivus LLC | $17.44 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Trevino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.